Cargando…
Predictors of Epicardial Fat Volume Decrease after Dapagliflozin Treatment in Patients with Type 2 Diabetes
Background and Objectives: Dapagliflozin treatment proved to reduce the epicardial fat volume (EFV) in patients with type 2 diabetes (T2D). Despite the reduction in EFV being associated with improved diastolic function in patients with T2D, EVF is not routinely evaluated in T2D because it is costly...
Autores principales: | Braha, Adina, Albai, Alin, Timar, Bogdan, Cipu, Daniela, Vasiluță, Lucian, Potre, Ovidiu, Timar, Romulus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777745/ https://www.ncbi.nlm.nih.gov/pubmed/35056329 http://dx.doi.org/10.3390/medicina58010021 |
Ejemplares similares
-
Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes
por: Braha, Adina, et al.
Publicado: (2020) -
Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors
por: Braha, Adina, et al.
Publicado: (2019) -
Validation and cross-cultural adaptation of the depression Patient’s Health Questionnaire – 9 in the Romanian population of patients with Type 2 Diabetes Mellitus
por: Lupascu, Nicoleta, et al.
Publicado: (2019) -
Instrument for Assessing Patients’ Desirability, Acceptability, and Adherence to Telemedicine in Diabetes: Development, Validity, and Reliability
por: Patrascu, Raul, et al.
Publicado: (2021) -
Factors Influencing the Desirability, Acceptability, and Adherence of Patients with Diabetes to Telemedicine
por: Patrascu, Raul, et al.
Publicado: (2022)